PFS
EPIX

Prospera Financial Services’s ESSA Pharma EPIX Stock Holding History

Prospera Financial Services’s Portfolio EPIX Stock Details EPIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-7,568
Closed -$47K – 1887
2022
Q1 		$47K Buy
+7,568
New +$66.5K ﹤0.01% 1401

Other funds holding EPIX

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Prospera Financial Services's EPIX Position: Q2 2022 in Review

Prospera Financial Services sold out of ESSA Pharma (EPIX) in Q2 2022, closing a stake of 7,568 shares — an estimated $47K sold.

Prospera Financial Services first reported a position in EPIX in Q1 2022 and held it in 1 quarter. The position peaked at $47K in Q1 2022. 59 funds tracked by Wall St. Rank hold EPIX as of Q2 2022.

  • Prospera Financial Services reported no remaining ESSA Pharma position as of Q2 2022 after selling out during the quarter.
  • Prospera Financial Services sold 7,568 ESSA Pharma shares in Q2 2022, an estimated $47K.
  • Prospera Financial Services first reported a position in ESSA Pharma in Q1 2022 and held it in 1 quarter.
  • Prospera Financial Services's ESSA Pharma position peaked at $47K in Q1 2022.
  • 59 funds tracked by Wall St. Rank held ESSA Pharma as of Q2 2022.

Based on Prospera Financial Services's 13F filing for Q2 2022, filed 8 Aug 2022.